Cholesterol-lowering treatment in chronic kidney disease: multistage pairwise and network meta-analyses

Autor: M. Montserrat Chimeno, Juan Bustamante-Munguira, Eric Alamartine, Álvaro Maurtua-Briseño-Meiggs, F. Javier Álvarez, Jesús Grande-Villoria, Miquel Vilardell, Débora Martín-García, Frank Lizaraso-Soto, Francisco Herrera-Gómez, Carlos Ochoa-Sangrador
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Revisión de la investigación por pares
medicine.medical_specialty
Atorvastatin
Hypercholesterolemia
Renal function
lcsh:Medicine
Context (language use)
Cholesterol treatment
Article
03 medical and health sciences
0302 clinical medicine
Ezetimibe
Internal medicine
Chronic kidney disease
medicine
Humans
Rosuvastatin
Insuficiencia renal crónica
lcsh:Science
Metaanálisis
Enfermedad renal crónica
Multidisciplinary
business.industry
lcsh:R
Bayes Theorem
Odds ratio
medicine.disease
030104 developmental biology
Risk factors
Nephrology
Kidney Failure
Chronic
lcsh:Q
Tratamiento para el colesterol
Drug Therapy
Combination
Hydroxymethylglutaryl-CoA Reductase Inhibitors
business
Colesterol
030217 neurology & neurosurgery
Mace
Kidney disease
medicine.drug
Glomerular Filtration Rate
Zdroj: Repositorio Académico USMP
Universidad San Martín de Porres-USMP
USMP-Institucional
Universidad de San Martín de Porres
instacron:USMP
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-11 (2019)
UVaDOC. Repositorio Documental de la Universidad de Valladolid
instname
Popis: Producción Científica
Pairwise and network meta-analyses on the relationship between the efficacy of the use of statins with or without ezetimibe and reductions in low-density lipoprotein cholesterol (LDLc) and C-reactive protein (CRP) in patients with chronic kidney disease (CKD) are presented. In the pairwise meta-analysis, statins with or without ezetimibe were shown to be efficacious in reducing major adverse cardiovascular events (MACE) in patients with CKD and an estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73 m2, in the context of both primary prevention [odds ratio (OR)/95% confidence interval (95% CI)/I2/number of studies (n): 0.50/0.40–0.64/0%/6] and primary/secondary prevention (0.66/0.57–0.76/57%/18). However, in the Bayesian network meta-analysis, compared to the placebo, only atorvastatin 80 mg daily and atorvastatin and rosuvastatin at doses equivalent to simvastatin 20 mg daily reduced the odds of MACEs in this patient population. The network meta-analysis for LDLc and CRP treatment objectives also showed that, regardless of eGFR and excluding dialysis patients, the number of MACEs decreased in patients with CKD, with reductions in both LDLc and CRP of less than 50% (surface under the cumulative ranking (SUCRA)/heterogeneity (vague)/n: 0.77/0.14/3). The evaluation of the benefits of drugs may lead to individualized therapy for CKD patients: Cholesterol-lowering treatment for CKD patients with high levels of both LDLc and CRP is suggested.
Junta de Castilla y León (grant VA161G18)
Databáze: OpenAIRE
Externí odkaz: